Post-earnings recap
Reported
Wed, May 10, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
63%
Protagonist Therapeutics reported a loss per share of $0.84, which did not meet expectations, but the stock still rose by 2.66%. This increase may reflect investor optimism about the company's ongoing clinical trials and product development efforts despite the lack of specific guidance. The market seems to be focusing on long-term potential rather than short-term earnings results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.84 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management highlighted ongoing efforts in clinical development but did not provide specific guidance for future performance. The tone was measured, reflecting the company's current stage.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical trials and product development.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—